GOLDEN, Colo., Nov. 28, 2022 /PRNewswire/ -- Theralink Technologies (OTC: THER) ("Theralink" or the "Company"), a precision oncology company with a novel phosphoprotein-based assay for breast cancer, ...

Evaluation of BRCA1/2 mutation status among women with triple-negative breast cancer. This is an ASCO Meeting Abstract from the 2014 ASCO Annual Meeting I. This abstract does not include a full text ...

Reverse phase protein array is a high-throughput technology that performs protein assays on thousands of samples simultaneously, including tissue and cell lysates, serum, plasma or other body fluids.

GOLDEN, Colo., Nov. 28, 2022 /PRNewswire/ -- Theralink Technologies (THER) (OTC: THER) ("Theralink" or the "Company"), a precision oncology company with a novel phosphoprotein-based assay for breast ...